Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Bone Turnover in Osteopenia
NCT04702516Phase 2Unknown
- Start
- Mar 2021
- Primary completion
- Aug 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteopenia comparing Semaglutide with Placebo (2 arms). Primary endpoint: Procollagen type 1 N-terminal propeptide at 52 weeks. Status: unknown.
02
Drugs
03
Conditions
osteopenia
Beyond the preview
Go deeper on NCT04702516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702516.